Challenge: As the global SARS-CoV-2 situation continues to evolve, the strategy of focusing vaccine development on the currently dominant variant of concern (eg. BA.4 and BA.5 in 2022, XBB.1.5 in 2023) should be complemented by approaches that provide more durable and wider protection against future, emerging variants that can be quickly manufactured for urgent deployment. Solution: The…
Challenge: Vaccination has historically shown effectiveness in preventing morbidity caused by infectious diseases. Therefore, the notion of developing cancer vaccines remains appealing as a combinatory approach with the current standard of care. Unfortunately, a long list of vaccines tested so far has not been successful in achieving the hoped-for clinical outcome. As a result, the past…
Challenge: A need exists for new drugs efficiently targeting fungi such as Candida albicans, which affects thousands of patients on its own every year in Canada and over the world. Similarly, to antibiotics, fungi also show an increase in resistance against first-line therapeutic agents, including some that are considered as major treats to public health. Solution: The research…
Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors. MONTREAL, January 12, 2024 – CQDM is proud to announce the appointment of Michele D’Elia, Executive Director, Medical and Scientific Affairs at Roche Diagnostics and Pierre Côte, Global Senior Director for immunology’s new pipeline portfolio at Sanofi to its board of directors. These…
Opportunity of Biopharma Networking during the “Connect-Bio: Médecine personnalisée” event in 22 days.CQDM and Axelys invite you to this Connect-BIO event, bringing together passionate researchers and entrepreneurs in the field of personalized medicine. The first part of the event will consist of an overview of the perspectives and issues linked to the development and commercialization…
CQDM. We grow. Are you known for your outstanding organizational skills, exceptional attention to detail, and collaborative mindset? Do you aspire to make meaningful contributions within a team, thriving in a dynamic work environment that offers diverse project opportunities? Join a team that is agile and dynamic, distinguished by its unique mission. The Administrative Coordinator…
CQDM. We connect.CQDM welcomes 3 new ”Network” Members: NanoBrand from Montreal, Two-Photon Research, also from Montreal and BrevisRefero Corporation from Toronto.We invite you to learn more about these 3 new “Network” Members as well as the advantages related to this type of CQDM membership via this link:https://cqdm.orgcqdm-membres-du-consortium-biopharmaceutique/The ”Network” membership is accessible and entitles you to…
CQDM. We collaborate.CQDM is proud to announce a new collaboration/broadcast/communication partnership with the Canada Foundation for Innovation/Fondation canadienne pour l’innovation via its Research Facilities Navigator.This new partnership will give greater scope to facilitated innovations in biopharma in the Quebec ecosystem and beyond.Launched in 2013 by the Canada Foundation for Innovation (CFI), the Research Facilities Navigator…
Call for collaborative research projects on precision care in oncology, presented by CQDM in collaboration with Oncopole – Pôle cancer du Fonds de recherche du Québec Santé.This program aims to support interventions with a personalized approach that optimize the treatment available to a person affected by cancer, and more specifically via oncogenetics, patient profiling and…
CQDM. We connect. CQDM is proud to welcome our new Network Member: RNA Technologies and Therapeutics! RNA Technologies and Therapeutics provides off-the shelf preclinical grade and high-quality codon optimized mRNA, and we also offer custom made mRNA in multiple scales (e.g., 1mg to 1g). Our business model encompasses co-development of mRNA products/therapeutics and have our…